Vascugen Inc.
Vascular diseases afflict hundreds of millions of people worldwide. Many patients do not respond to standard treatments. We are developing regenerative medicines to address these unmet needs. Vascugen is dedicated to revolutionizing the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow to tissues. Particularly for diabetic patients at high risk for limb amputation and associated morbidity. The company’s lead program is an induced-pluripotent stem cell (iPSC)-derived vasculogenic cell with the potential to forge new blood vessels in oxygen-starved tissues.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
Vascugen launched in 2018 in partnership with Indiana University (IU), a leading institution for medical research. Our mission is to develop advanced medicines for life-threatening conditions which result from insufficient microvascular circulation. These conditions often arise as a complication of diabetes or arterial disease. Afflicted patients lack treatment options and are at high risk for major amputations and death. We are advancing a potent cell replacement therapy designed to form microvascular structures and thereby restore circulation.
Technology
Vascugen has exclusive rights from Indiana University (IU) to a broad technology portfolio developed in the laboratory of our scientific founder, Mervin C. Yoder, MD. Our goal is to advance an allogeneic, donor-independent cell replacement therapy that is directly capable of microvascular regeneration. To achieve this, we have established partnerships that provide access to two Nobel Prize winning technologies, induced pluripotent stem cells (iPSCs) & gene modification.